Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

Inclusion Criteria: * Male and female subjects ≥18 years of age * In good general health as determined by a thorough medical history and physical examination, and vital signs * Clinical diagnosis of mild to moderate atopic dermatitis according to the criteria of Hanifin and Rajka * Mild to moderate Atopic Dermatitis area and severity index \[EASI\] 10-21 * A score of at least ≥ 5 points (moderate pruritus) on the VAS for pruritus * A minimum of 10% and not more than 30% of the subjects' BSA affected by atopic dermatitis (affected is defined by physical examination findings: erythema, edema, scaling, lichenification, excoriation, with the excoriation serving as the physical examination correlate of pruritus) * An IGA score of 2-3 * Patient has a history of AD for ≥12 months * Ability to read and understand English and to provide written informed consent and authorization for protected health information disclosure Exclusion Criteria: * Pregnant and lactating women by urine pregnancy testing * Subjects with any significant clinical abnormalities which may interfere with study participation * Any skin condition which may interfere with evaluation of AD * Atopic dermatitis only on the head or scalp * Subjects with Atopic dermatitis on the face * Unstable or actively infected atopic dermatitis * Patients suffering from pruritus from conditions other than AD * Patients with chronic pruritus due to systemic disease * Patients with conditions requiring inhaled steroids * Have concurrent skin disease of such severity in the study area that it could interfere with the study evaluation * Have active skin infections on the treatment area * Have received or planning to receive topical corticosteroids, topical coal tar, topical sulfur, topical PDE-4 inhibitors, topical antihistamines, topical antiseptics or antibiotics, topical antifungals, bleach baths, UVA or UVB phototherapy, oral/IV/inhaled steroids, antibiotics/antiviral/antifungal agents, oral probiotics, glucocorticoids treatment, calcineurin inhibitors, immunomodulating biologic agents, systemic glucocorticoids, systemic immunosuppressive or immunomodulatory agents within 2 weeks of Baseline visit. * Current or recent history (≤3 months of systemic use of Otrexup™, Rasuvo®, Rheumatrex® and Trexall™ or its generic versions such as Methotrexate * History of being seropositive for human immunodeficiency virus (HIV) at screening by laboratory testing at Screening * History of being positive for Hepatitis B virus surface antigen (HBsAg) or positive Hepatitis C virus antibody (HCV Ab) at screening by laboratory testing at Screening * History of renal disease * Use of any investigational drugs within the previous 30 days prior to dosing or within a period of less than five times the drug's half-life, whichever is longer * Use of any biologic within a period of 5 times its half-life * Use of vinegar or bleach baths within 2 weeks of starting the study